Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec ( BIIB) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 1.6%. By the end of trading, Biogen Idec fell $28.51 (-8.2%) to $318.53 on heavy volume. Throughout the day, 5,380,893 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,384,400 shares. The stock ranged in price between $313.08-$355.00 after having opened the day at $355.00 as compared to the previous trading day's close of $347.04. Other companies within the Health Care sector that declined today were: China Pharma ( CPHI), down 31.6%, IsoRay ( ISR), down 26.7%, Arrowhead Research Corporation ( ARWR), down 13.1% and Semler Scientific ( SMLR), down 12.7%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $82.7 billion and is part of the drugs industry. Shares are up 24.1% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Endocyte ( ECYT), up 92.4%, Aastrom Biosciences ( ASTM), up 30.6%, Palatin Technologies ( PTN), up 17.1% and Enzon Pharmaceuticals ( ENZN), up 16.7% , were all gainers within the health care sector with InterMune ( ITMN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

UK GDP Hits Slowest Pace in Five Years as Cold Snap Hammers Construction

UK GDP Hits Slowest Pace in Five Years as Cold Snap Hammers Construction

Amazon Shares on Record Path, Challenging Apple as World's Biggest Company

Amazon Shares on Record Path, Challenging Apple as World's Biggest Company

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Global Stocks Rise on Tech Resurgence; Dollar Past 3-Month High Ahead of Q1 GDP

Daimler Shares Rise After Record Mercedes-Benz Sales, Bullish Profit Outlook

Daimler Shares Rise After Record Mercedes-Benz Sales, Bullish Profit Outlook

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI